amsacrine has been researched along with Diarrhea in 2 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 7.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "We varied the number of doses of high-dose cytarabine (3 g/m2) given to patients with acute leukemia in relapse who were receiving therapeutic doses of amsacrine (600 mg/m2/course)." | 3.67 | Treatment of acute leukemia with amsacrine and high-dose cytarabine. ( Ahmed, T; Arlin, ZA; Friedland, M; Gaddipati, J; Mittelman, A; Rieber, E, 1985) |
| "Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC." | 2.71 | Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. ( Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sung, WJ | 1 |
| Kim, DH | 1 |
| Sohn, SK | 1 |
| Kim, JG | 1 |
| Baek, JH | 1 |
| Jeon, SB | 1 |
| Moon, JH | 1 |
| Ahn, BM | 1 |
| Lee, KB | 1 |
| Arlin, ZA | 1 |
| Gaddipati, J | 1 |
| Ahmed, T | 1 |
| Mittelman, A | 1 |
| Friedland, M | 1 |
| Rieber, E | 1 |
1 trial available for amsacrine and Diarrhea
| Article | Year |
|---|---|
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diar | 2005 |
1 other study available for amsacrine and Diarrhea
| Article | Year |
|---|---|
Treatment of acute leukemia with amsacrine and high-dose cytarabine.
Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine | 1985 |